Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study.
Ndivhuho A Makhado, Edith Matabane, Mauro Faccin...
https://pubmed.ncbi.nlm.nih.gov/30342828/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-05-06
26436
Participants Needed
16
Research Sites
N/A
Total Duration
Researchers are evaluating new diagnostic tests to improve the detection and management of tuberculosis TB, a disease that leaves many undiagnosed and causes significant mortality worldwide. This study, known as the Rapid Research in Diagnostics Development for TB Network R2D2 TB Network, aims to assess early-stage TB triage, diagnostic, and drug resistance tests in real-world clinical settings across multiple countries. The goal is to identify faster, simpler, and less expensive tools to reduce the current gaps in timely TB diagnosis and treatment initiation. The study involves testing various novel diagnostic methods, including sputum-based and non-sputum biomarker tests, molecular assays, breath-based tests, and artificial intelligence tools to analyze images and sounds related to TB diagnosis. These tests will be compared to established reference standards like sputum culture and molecular resistance testing. The study also evaluates the usability of these tests through observations and surveys of health workers. Participants include adults with symptoms or risk factors for TB, and patients with rifampin-resistant TB for drug susceptibility test evaluations. Participants will undergo diagnostic testing and clinical assessments, with follow-up visits scheduled to monitor test performance and usability. Researchers will measure the sensitivity and specificity of these novel tests over a seven-month period. The study also tracks the ability of health workers to effectively use the new diagnostic tools. Overall participation duration varies by individual, and the study aims to provide comprehensive data to enhance TB diagnosis and treatment worldwide.
CONDITIONS
Rapid Research in Diagnostics Development for TB Network
A
Adithya Cattamanchi, MD
C
Catherine Cook, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
University Hospital Heidelberg
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 7 months
Participants undergo evaluation with various novel tuberculosis triage, diagnostic, and drug resistance tests to assess their accuracy and usability.
Initial and follow-up visits as needed for sample collection and testing
Duration - Up to 7 months
Participants are observed for outcomes related to test performance and health status over time.
Visits scheduled as part of the follow-up assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ndivhuho A Makhado, Edith Matabane, Mauro Faccin...
https://pubmed.ncbi.nlm.nih.gov/30342828/Simon Walusimbi, Freddie Bwanga, Ayesha De Costa...
https://pubmed.ncbi.nlm.nih.gov/24172543/Morad K Nakhleh, Raneen Jeries, A'laa Gharra...
https://pubmed.ncbi.nlm.nih.gov/24789953/John Z Metcalfe, Elizabeth Streicher, Grant Theron...
https://pubmed.ncbi.nlm.nih.gov/28893776/Damien Portevin, Felicien Moukambi, Petra Clowes...
https://pubmed.ncbi.nlm.nih.gov/25185458/Luisa Paris, Ruben Magni, Fatima Zaidi...
https://pubmed.ncbi.nlm.nih.gov/29237757/Neel R Gandhi, Anthony Moll, A Willem Sturm...
https://pubmed.ncbi.nlm.nih.gov/17084757/Rajendra Prasad, Abhijeet Singh, Viswesvaran Balasubramanian...
https://pubmed.ncbi.nlm.nih.gov/28749390/Rebecca Crowder, Balamugesh Thangakunam, Alfred Andama...
https://pubmed.ncbi.nlm.nih.gov/39509711/Margaretha de Vos, Serej D Ley, Kristin B Wiggins...
https://pubmed.ncbi.nlm.nih.gov/31141643/University of California, San Francisco
Lead Sponsor
University Hospital Heidelberg
Collaborating Sponsor